
Biogen (BIIB) Stock Forecast & Price Target
Biogen (BIIB) Analyst Ratings
Bulls say
Biogen is a well-established biopharmaceutical company with a strong track record of success in treating neurodegenerative and rare diseases. Its diverse revenue streams, including collaborations and newer franchises, provide a solid foundation for future growth and financial stability. The company has a promising pipeline with key catalysts approaching, and its commitment to sustainability and diversity is commendable. While there are some risks, including competition and potential setbacks, the company's strategic initiatives and strong financial performance make it an attractive long-term investment opportunity.
Bears say
Biogen is an established biopharmaceutical company that has been facing numerous challenges in recent years. The company's declining multiple sclerosis franchise, which is its largest revenue generator, has been facing increasing competition and pricing pressures. In addition, Biogen's newer franchises, including Spinraza and Leqembi, have not been able to fully offset the declining sales from its MS drugs. Furthermore, the company is heavily reliant on its collaboration agreements with Roche and other partners, which can be unpredictable and may not generate consistent revenue in the long term. This, combined with Biogen's high operating expenses and ongoing pipeline challenges, leads to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.
Biogen (BIIB) Analyst Forecast & Price Prediction
Start investing in Biogen (BIIB)
Order type
Buy in
Order amount
Est. shares
0 shares